Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Results from the Phase III CheckMate 77T study were published today in the New England Journal...
MD Anderson Research Highlights for October 25, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ESMO: Erdafitinib demonstrates improved responses in FGFR-altered advanced urinary tract cancers
ABSTRACTS: 2359O, 2362MO
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses...
ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
ABSTRACT: LBA41
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center. The...
mRNA delivered by extracellular vesicles induces immunotherapy response in glioblastoma
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to...
Lactate-producing bacteria inside tumors promote resistance to radiation therapy
Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance...
MD Anderson Research Highlights: ESMO 2023 Special Edition
ABSTRACTS: LBA71, 1088MO, 95MO, LBA48, 1082O, 1085O, LBA34, 243MO
The University of Texas MD Anderson Cancer Center’s Research Highlights...
MD Anderson hosts 2023 Leading Edge of Cancer Research Symposium
The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring...
Jennifer Wargo, M.D., elected to the National Academy of Medicine
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine and core member of the James P. Allison...
MD Anderson launches collaborative initiative to reduce breast cancer disparities in Houston area
The University of Texas MD Anderson Cancer Center today announced the launch of Texas Health Equity Alliance for Breast Cancer (THEAL), a...
MD Anderson Research Highlights for October 4, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Alejandro Aballay, Pharm.D., Ph.D., named Dean of MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
The University of Texas MD Anderson Cancer Center and The University of Texas Health Science Center at Houston today announced Alejandro Aballay...